Protalix BioTherapeutics (NYSE:PLX) Coverage Initiated by Analysts at initiated coverage on shares of Protalix BioTherapeutics (NYSE:PLXGet Rating) in a report issued on Tuesday morning. The firm issued a hold rating on the stock.

Shares of Protalix BioTherapeutics stock opened at $1.36 on Tuesday. The company has a debt-to-equity ratio of 130.59, a current ratio of 1.86 and a quick ratio of 1.32. Protalix BioTherapeutics has a 1 year low of $0.70 and a 1 year high of $6.64. The company has a market cap of $62.99 million, a P/E ratio of -2.19 and a beta of 2.27.

Protalix BioTherapeutics Company Profile (Get Rating)

Protalix BioTherapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in Israel, Brazil, rest of Latin America, and internationally. The company offers Elelyso for the treatment of Gaucher disease.

Read More

Receive News & Ratings for Protalix BioTherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protalix BioTherapeutics and related companies with's FREE daily email newsletter.